|
Fusion Gene Summary | |
Fusion Gene ORF analysis | |
Fusion Genomic Features | |
Fusion Protein Features | |
Fusion Gene Sequence | |
Fusion Gene PPI analysis | |
Related Drugs | |
Related Diseases |
Fusion gene:NAALADL2-AMACR (FusionGDB2 ID:HG254827TG23600) |
Fusion Gene Summary for NAALADL2-AMACR |
Fusion gene summary |
Fusion gene information | Fusion gene name: NAALADL2-AMACR | Fusion gene ID: hg254827tg23600 | Hgene | Tgene | Gene symbol | NAALADL2 | AMACR | Gene ID | 254827 | 23600 |
Gene name | N-acetylated alpha-linked acidic dipeptidase like 2 | alpha-methylacyl-CoA racemase | |
Synonyms | - | AMACRD|CBAS4|P504S|RACE|RM | |
Cytomap | ('NAALADL2')('AMACR') 3q26.31 | 5p13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2N-acetylated alpha-linked acidic dipeptidase 2NAALADase L2glutamate carboxypeptidase II-type non-peptidase homologue | alpha-methylacyl-CoA racemase2-methylacyl-CoA racemase | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | Q58DX5 | Q9UHK6 | |
Ensembl transtripts involved in fusion gene | ENST00000473253, ENST00000454872, | ||
Fusion gene scores | * DoF score | 28 X 19 X 9=4788 | 28 X 3 X 4=336 |
# samples | 29 | 23 | |
** MAII score | log2(29/4788*10)=-4.04529834692857 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(23/336*10)=-0.546827371834385 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: NAALADL2 [Title/Abstract] AND AMACR [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | NAALADL2(175042114)-AMACR(34006004), # samples:1 | ||
Anticipated loss of major functional domain due to fusion event. | NAALADL2-AMACR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NAALADL2-AMACR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. NAALADL2-AMACR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. NAALADL2-AMACR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | AMACR | GO:0008206 | bile acid metabolic process | 10655068 |
Fusion gene breakpoints across NAALADL2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene breakpoints across AMACR (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerDB4 | PRAD | TCGA-YL-A8SC | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
Top |
Fusion Gene ORF analysis for NAALADL2-AMACR |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3CDS | ENST00000473253 | ENST00000335606 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-3CDS | ENST00000473253 | ENST00000382072 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000382068 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000382085 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000426255 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000441713 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000502637 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000512079 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
3UTR-5UTR | ENST00000473253 | ENST00000514195 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000382068 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000382085 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000426255 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000441713 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000502637 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000512079 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
5CDS-5UTR | ENST00000454872 | ENST00000514195 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
In-frame | ENST00000454872 | ENST00000335606 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
In-frame | ENST00000454872 | ENST00000382072 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - |
ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000454872 | NAALADL2 | chr3 | 175042114 | + | ENST00000335606 | AMACR | chr5 | 34006004 | - | 5035 | 1218 | 128 | 2119 | 663 |
ENST00000454872 | NAALADL2 | chr3 | 175042114 | + | ENST00000382072 | AMACR | chr5 | 34006004 | - | 3878 | 1218 | 128 | 1567 | 479 |
DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000454872 | ENST00000335606 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - | 0.000190484 | 0.99980956 |
ENST00000454872 | ENST00000382072 | NAALADL2 | chr3 | 175042114 | + | AMACR | chr5 | 34006004 | - | 0.000300507 | 0.9996995 |
Top |
Fusion Genomic Features for NAALADL2-AMACR |
FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
Top |
Fusion Protein Features for NAALADL2-AMACR |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr3:175042114/chr5:34006004) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
NAALADL2 | AMACR |
FUNCTION: May be catalytically inactive. | FUNCTION: Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters (PubMed:7649182, PubMed:10655068, PubMed:11060359). Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither 3-methyl-branched nor linear-chain acyl-CoAs (PubMed:7649182, PubMed:10655068, PubMed:11060359). {ECO:0000269|PubMed:10655068, ECO:0000269|PubMed:11060359, ECO:0000269|PubMed:7649182}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | NAALADL2 | chr3:175042114 | chr5:34006004 | ENST00000454872 | + | 5 | 14 | 1_121 | 363 | 796.0 | Topological domain | Cytoplasmic |
Hgene | NAALADL2 | chr3:175042114 | chr5:34006004 | ENST00000454872 | + | 5 | 14 | 122_142 | 363 | 796.0 | Transmembrane | Helical%3B Signal-anchor for type II membrane protein |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000335606 | 0 | 5 | 380_382 | 82 | 383.0 | Motif | Microbody targeting signal | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382072 | 0 | 4 | 380_382 | 82 | 199.0 | Motif | Microbody targeting signal | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382085 | 0 | 6 | 380_382 | 82 | 395.0 | Motif | Microbody targeting signal | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000441713 | 0 | 4 | 380_382 | 82 | 230.0 | Motif | Microbody targeting signal | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000335606 | 0 | 5 | 121_126 | 82 | 383.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382072 | 0 | 4 | 121_126 | 82 | 199.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382085 | 0 | 6 | 121_126 | 82 | 395.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000441713 | 0 | 4 | 121_126 | 82 | 230.0 | Region | Substrate binding |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Hgene | NAALADL2 | chr3:175042114 | chr5:34006004 | ENST00000454872 | + | 5 | 14 | 143_795 | 363 | 796.0 | Topological domain | Extracellular |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000335606 | 0 | 5 | 55_58 | 82 | 383.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382072 | 0 | 4 | 55_58 | 82 | 199.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000382085 | 0 | 6 | 55_58 | 82 | 395.0 | Region | Substrate binding | |
Tgene | AMACR | chr3:175042114 | chr5:34006004 | ENST00000441713 | 0 | 4 | 55_58 | 82 | 230.0 | Region | Substrate binding |
Top |
Fusion Gene Sequence for NAALADL2-AMACR |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>57023_57023_1_NAALADL2-AMACR_NAALADL2_chr3_175042114_ENST00000454872_AMACR_chr5_34006004_ENST00000335606_length(transcript)=5035nt_BP=1218nt TTATTCACAGAAGAAAGCAGGTAGTATACTGTTACAATACTACAGTAGAAAGTCAGAAGGTCACAAAGCTTGCAGGGTAAGTGACACAAC TTGAAACTGCTTGGCCCTCTTTAAAAAGAAATAATAAAATGGGAGAGAATGAAGCAAGTTTACCTAACACGTCTTTGCAAGGTAAAAAGA TGGCCTATCAGAAGGTCCATGCAGATCAAAGAGCTCCAGGACACTCACAGTACTTAGACAATGATGACCTTCAAGCCACTGCCCTTGACT TAGAGTGGGACATGGAGAAGGAACTAGAGGAGTCTGGTTTTGACCAATTCCAGCTAGACGGTGCTGAGAATCAGAACCTAGGGCATTCAG AGACTATAGACCTCAATCTTGATTCCATTCAACCAGCAACTTCACCCAAAGGAAGGTTCCAGAGACTTCAAGAAGAATCTGACTACATTA CCCATTATACACGATCTGCACCAAAGAGCAATCGCTGCAACTTTTGCCACGTCTTAAAAATACTTTGCACAGCCACCATTTTATTTATTT TTGGGATTTTGATAGGTTATTATGTACATACAAATTGCCCTTCAGATGCTCCATCTTCAGGAACAGTTGATCCTCAGTTATATCAAGAGA TTCTCAAGACAATCCAGGCAGAAGATATTAAGAAGTCTTTCAGAAATTTGGTACAACTATATAAAAATGAAGATGACATGGAAATTTCAA AGAAGATTAAGACTCAGTGGACCTCTTTGGGCCTAGAAGATGTACAGTTTGTAAATTACTCTGTGCTGCTTGATCTGCCAGGCCCTTCTC CCAGCACTGTGACTCTGAGCAGCAGTGGTCAATGCTTTCATCCTAATGGCCAGCCTTGCAGTGAAGAAGCCAGAAAAGATAGCAGCCAAG ACCTGCTCTATTCATATGCAGCCTATTCTGCCAAAGGAACTCTCAAGGCTGAAGTCATCGATGTGAGTTATGGAATGGCAGATGATTTAA AAAGGATTAGGAAAATAAAAAACGTAACAAATCAGATCGCACTCCTGAAATTAGGAAAATTGCCACTGCTTTATAAGCTTTCCTCATTGG AAAAGGCTGGATTTGGAGGTGTTCTTCTGTATATCGATCCTTGTGATTTGCCAAAGACTGTGAATCCTAGCCATGATACCTTCATGGTGT CACTGAATCCAGGAGGAGACCCTTCTACGCCTGGTTACCCAAGTGTCGGTGTCATGGAGAAACTCCAGCTGGGCCCAGAGATTCTGCAGC GGGAAAATCCAAGGCTTATTTATGCCAGGCTGAGTGGATTTGGCCAGTCAGGAAGCTTCTGCCGGTTAGCTGGCCACGATATCAACTATT TGGCTTTGTCAGGTGTTCTCTCAAAAATTGGCAGAAGTGGTGAGAATCCGTATGCCCCGCTGAATCTCCTGGCTGACTTTGCTGGTGGTG GCCTTATGTGTGCACTGGGCATTATAATGGCTCTTTTTGACCGCACACGCACTGGCAAGGGTCAGGTCATTGATGCAAATATGGTGGAAG GAACAGCATATTTAAGTTCTTTTCTGTGGAAAACTCAGAAATTGAGTCTGTGGGAAGCACCTCGAGGACAGAACATGTTGGATGGTGGAG CACCTTTCTATACGACTTACAGGACAGCAGATGGGGAATTCATGGCTGTTGGAGCAATAGAACCCCAGTTCTACGAGCTGCTGATCAAAG GACTTGGACTAAAGTCTGATGAACTTCCCAATCAGATGAGCATGGATGATTGGCCAGAAATGAAGAAGAAGTTTGCAGATGTATTTGCAG AGAAGACGAAGGCAGAGTGGTGTCAAATCTTTGACGGCACAGATGCCTGTGTGACTCCGGTTCTGACTTTTGAGGAGGTTGTTCATCATG ATCACAACAAGGAACGGGGCTCGTTTATCACCAGTGAGGAGCAGGACGTGAGCCCCCGCCCTGCACCTCTGCTGTTAAACACCCCAGCCA TCCCTTCTTTCAAAAGGGATCCTTTCATAGGAGAACACACTGAGGAGATACTTGAAGAATTTGGATTCAGCCGCGAAGAGATTTATCAGC TTAACTCAGATAAAATCATTGAAAGTAATAAGGTAAAAGCTAGTCTCTAACTTCCAGGCCCACGGCTCAAGTGAATTTGAATACTGCATT TACAGTGTAGAGTAACACATAACATTGTATGCATGGAAACATGGAGGAACAGTATTACAGTGTCCTACCACTCTAATCAAGAAAAGAATT ACAGACTCTGATTCTACAGTGATGATTGAATTCTAAAAATGGTTATCATTAGGGCTTTTGATTTATAAAACTTTGGGTACTTATACTAAA TTATGGTAGTTATTCTGCCTTCCAGTTTGCTTGATATATTTGTTGATATTAAGATTCTTGACTTATATTTTGAATGGGTTCTAGTGAAAA AGGAATGATATATTCTTGAAGACATCGATATACATTTATTTACACTCTTGATTCTACAATGTAGAAAATGAGGAAATGCCACAAATTGTA TGGTGATAAAAGTCACGTGAAACAGAGTGATTGGTTGCATCCAGGCCTTTTGTCTTGGTGTTCATGATCTCCCTCTAAGCACATTCCAAA CTTTAGCAACAGTTATCACACTTTGTAATTTGCAAAGAAAAGTTTCACCTGTATTGAATCAGAATGCCTTCAACTGAAAAAAACATATCC AAAATAATGAGGAAATGTGTTGGCTCACTACGTAGAGTCCAGAGGGACAGTCAGTTTTAGGGTTGCCTGTATCCAGTAACTCGGGGCCTG TTTCCCCGTGGGTCTCTGGGCTGTCAGCTTTCCTTTCTCCATGTGTTTGATTTCTCCTCAGGCTGGTAGCAAGTTCTGGATCTTATACCC AACACACAGCAACATCCAGAAATAAAGATCTCAGGACCCCCCAGCAAGTCGTTTTGTGTCTCCTTGGACTGAGTTAAGTTACAAGCCTTT CTTATACCTGTCTTTGACAAAGAAGACGGGATTGTCTTTACATAAAACCAGCCTGCTCCTGGAGCTTCCCTGGACTCAACTTCCTAAAGG CATGTGAGGAAGGGGTAGATTCCACAATCTAATCCGGGTGCCATCAGAGTAGAGGGAGTAGAGAATGGATGTTGGGTAGGCCATCAATAA GGTCCATTCTGCGCAGTATCTCAACTGCCGTTCAACAATCGCAAGAGGAAGGTGGAGCAGGTTTCTTCATCTTACAGTTGAGAAAACAGA GACTCAGAAGGGCTTCTTAGTTCATGTTTCCCTTAGCGCCTCAGTGATTTTTTCATGGTGGCTTAGGCCAAAAGAAATATCTAACCATTC AATTTATAAATAATTAGGTCCCCAACGAATTAAATATTATGTCCTACCAACTTATTAGCTGCTTGAAAAATATAATACACATAAATAAAA AAATATATTTTTCATTTCTATTTCATTGTTAATCACAACTACTTACTAAGGAGATGTATGCACCTATTGGACACTGTGCAACTTCTCACC TGGAATGAGATTGGACACTGCTGCCCTCATTTTCTGCTCCATGTTGGTGTCCATATAGTACTTGATTTTTTATCAGATGGCCTGGAAAAC CCAGTCTCACAAAAATATGAAATTATCAGAAGGATTATAGTGCAATCTTATGTTGAAAGAATGAACTACCTCACTAGTAGTTCACGTGAT GTCTGACAGATGTTGAGTTTCATTGTGTTTGTGTGTTCAAATTTTTAAATATTCTGAGATACTCTTGTGAGGTCACTCTAATGCCCTGGG TGCCTTGGCACAGTTTTAGAAATACCAGTTGAAAATATTTGCTCAGGAATATGCAACTAGGAAGGGGCAGAATCAGAATTTAAGCTTTCA TATTCTAGCCTTCAGTCTTGTTCTTCAACCATTTTTAGGAACTTTCCCATAAGGTTATGTTTTCCAGCCCAGGCATGGAGGATCACTTGA GGCCAAGAGTTCGAGACCAGCCTGGGGAACTTGGCTGGACCTCCGTTTCTACGAAATAAAAATAAAAAAATTATCCAGGTATGGTGGTGT GTGCCTGTAGTCCTATCTACTCAAGGGTGGGGCAGGAGGATCACTTGAGCCCAGGAATTTGAGGCCACAGTGAATTAGGATTGCACCACT GCACTCTAGCCCAGGCAACAGAACAAGAACCTGTCTCTAAATAAATAAATAAAAATAATAATAATAAAAAAGATGTTTTCCCTACAACTC AGACTTTTCATTTGAACTCGGTCCAGCAAGGAAAATATAACCCACTCGAAGTCTTTAAAACAGAGGAAATTTAATATAAAGAATTCCACT GGTGACGAAAGAGCAGAGAAGCCCAGAAGATAGTGAGGCAACCCTGATAGGAACATAACTAGGAAGCCAAGACCACTCCTATGGTTGCAG GGGTGATGGGAAAGCTGGTGTACTTGGACCCAGAAGCCAAAGTTGCTGCACCCACCTTGGAGACATAGACACTGGCAGTAATACCTCAGG GAGAAGAAAGAAATCTAGGGAAATATCCTGGCTTCTTTCCTTCTCTCTCTCCCCTAGTCTTCCTACCAGTGTCTCCCATTAGCCAAATCT ACCTAGAAGCCAGAAAACAAGGGAACCCTGGAAATGTAGCCCCATAAGATAAAGAGCACCAAAGGAAATAGATCTGAGCAGACAGGCAGC ACAAAATGCAGTGTGTATGGTTTATTCACTCAGTAATTCCTTTAGCAAATGTTTATTGAGGATCTACTAGGTGCCAGGTATCATGATACT TGCTGGGGATACCATAATGAACAAAACAGACCTGTTCTCCGCTCTTGAGGAAATCAAAGACAAACACAGGATATGGAATAAACCCAGAAT TATCTCATTGTAAAATGTGTTAAGTACCACGAGGAGAAATATCAGGGCGATCTGACACAGCTAATGATTTGAAGAAGGGTGTGACCTGCC >57023_57023_1_NAALADL2-AMACR_NAALADL2_chr3_175042114_ENST00000454872_AMACR_chr5_34006004_ENST00000335606_length(amino acids)=663AA_BP=361 MGENEASLPNTSLQGKKMAYQKVHADQRAPGHSQYLDNDDLQATALDLEWDMEKELEESGFDQFQLDGAENQNLGHSETIDLNLDSIQPA TSPKGRFQRLQEESDYITHYTRSAPKSNRCNFCHVLKILCTATILFIFGILIGYYVHTNCPSDAPSSGTVDPQLYQEILKTIQAEDIKKS FRNLVQLYKNEDDMEISKKIKTQWTSLGLEDVQFVNYSVLLDLPGPSPSTVTLSSSGQCFHPNGQPCSEEARKDSSQDLLYSYAAYSAKG TLKAEVIDVSYGMADDLKRIRKIKNVTNQIALLKLGKLPLLYKLSSLEKAGFGGVLLYIDPCDLPKTVNPSHDTFMVSLNPGGDPSTPGY PSVGVMEKLQLGPEILQRENPRLIYARLSGFGQSGSFCRLAGHDINYLALSGVLSKIGRSGENPYAPLNLLADFAGGGLMCALGIIMALF DRTRTGKGQVIDANMVEGTAYLSSFLWKTQKLSLWEAPRGQNMLDGGAPFYTTYRTADGEFMAVGAIEPQFYELLIKGLGLKSDELPNQM SMDDWPEMKKKFADVFAEKTKAEWCQIFDGTDACVTPVLTFEEVVHHDHNKERGSFITSEEQDVSPRPAPLLLNTPAIPSFKRDPFIGEH -------------------------------------------------------------- >57023_57023_2_NAALADL2-AMACR_NAALADL2_chr3_175042114_ENST00000454872_AMACR_chr5_34006004_ENST00000382072_length(transcript)=3878nt_BP=1218nt TTATTCACAGAAGAAAGCAGGTAGTATACTGTTACAATACTACAGTAGAAAGTCAGAAGGTCACAAAGCTTGCAGGGTAAGTGACACAAC TTGAAACTGCTTGGCCCTCTTTAAAAAGAAATAATAAAATGGGAGAGAATGAAGCAAGTTTACCTAACACGTCTTTGCAAGGTAAAAAGA TGGCCTATCAGAAGGTCCATGCAGATCAAAGAGCTCCAGGACACTCACAGTACTTAGACAATGATGACCTTCAAGCCACTGCCCTTGACT TAGAGTGGGACATGGAGAAGGAACTAGAGGAGTCTGGTTTTGACCAATTCCAGCTAGACGGTGCTGAGAATCAGAACCTAGGGCATTCAG AGACTATAGACCTCAATCTTGATTCCATTCAACCAGCAACTTCACCCAAAGGAAGGTTCCAGAGACTTCAAGAAGAATCTGACTACATTA CCCATTATACACGATCTGCACCAAAGAGCAATCGCTGCAACTTTTGCCACGTCTTAAAAATACTTTGCACAGCCACCATTTTATTTATTT TTGGGATTTTGATAGGTTATTATGTACATACAAATTGCCCTTCAGATGCTCCATCTTCAGGAACAGTTGATCCTCAGTTATATCAAGAGA TTCTCAAGACAATCCAGGCAGAAGATATTAAGAAGTCTTTCAGAAATTTGGTACAACTATATAAAAATGAAGATGACATGGAAATTTCAA AGAAGATTAAGACTCAGTGGACCTCTTTGGGCCTAGAAGATGTACAGTTTGTAAATTACTCTGTGCTGCTTGATCTGCCAGGCCCTTCTC CCAGCACTGTGACTCTGAGCAGCAGTGGTCAATGCTTTCATCCTAATGGCCAGCCTTGCAGTGAAGAAGCCAGAAAAGATAGCAGCCAAG ACCTGCTCTATTCATATGCAGCCTATTCTGCCAAAGGAACTCTCAAGGCTGAAGTCATCGATGTGAGTTATGGAATGGCAGATGATTTAA AAAGGATTAGGAAAATAAAAAACGTAACAAATCAGATCGCACTCCTGAAATTAGGAAAATTGCCACTGCTTTATAAGCTTTCCTCATTGG AAAAGGCTGGATTTGGAGGTGTTCTTCTGTATATCGATCCTTGTGATTTGCCAAAGACTGTGAATCCTAGCCATGATACCTTCATGGTGT CACTGAATCCAGGAGGAGACCCTTCTACGCCTGGTTACCCAAGTGTCGGTGTCATGGAGAAACTCCAGCTGGGCCCAGAGATTCTGCAGC GGGAAAATCCAAGGCTTATTTATGCCAGGCTGAGTGGATTTGGCCAGTCAGGAAGCTTCTGCCGGTTAGCTGGCCACGATATCAACTATT TGGCTTTGTCAGGTGGAAGGAACAGCATATTTAAGTTCTTTTCTGTGGAAAACTCAGAAATTGAGTCTGTGGGAAGCACCTCGAGGACAG AACATGTTGGATGGTGGAGCACCTTTCTATACGACTTACAGGACAGCAGATGGGGAATTCATGGCTGTTGGAGCAATAGAACCCCAGTTC TACGAGCTGCTGATCAAAGGACTTGGACTAAAGTCTGATGAACTTCCCAATCAGATGAGCATGGATGATTGGCCAGAAATGAAGAAGAAG TTTGCAGATGTATTTGCAGAGAAGACGAAGGCAGAGTGGTGTCAAATCTTTGACGGCACAGATGCCTGTGTGACTCCGGTTCTGACTTTT GAGGAGGTTGTTCATCATGATCACAACAAGGAACGGGGCTCGTTTATCACCAGTGAGGAGCAGGACGTGAGCCCCCGCCCTGCACCTCTG CTGTTAAACACCCCAGCCATCCCTTCTTTCAAAAGGGATCCTTTCATAGGAGAACACACTGAGGAGATACTTGAAGAATTTGGATTCAGC CGCGAAGAGATTTATCAGCTTAACTCAGATAAAATCATTGAAAGTAATAAGGTAAAAGCTAGTCTCTAACTTCCAGGCCCACGGCTCAAG TGAATTTGAATACTGCATTTACAGTGTAGAGTAACACATAACATTGTATGCATGGAAACATGGAGGAACAGTATTACAGTGTCCTACCAC TCTAATCAAGAAAAGAATTACAGACTCTGATTCTACAGTGATGATTGAATTCTAAAAATGGTTATCATTAGGGCTTTTGATTTATAAAAC TTTGGGTACTTATACTAAATTATGGTAGTTATTCTGCCTTCCAGTTTGCTTGATATATTTGTTGATATTAAGATTCTTGACTTATATTTT GAATGGGTTCTAGTGAAAAAGGAATGATATATTCTTGAAGACATCGATATACATTTATTTACACTCTTGATTCTACAATGTAGAAAATGA GGAAATGCCACAAATTGTATGGTGATAAAAGTCACGTGAAACAGAGTGATTGGTTGCATCCAGGCCTTTTGTCTTGGTGTTCATGATCTC CCTCTAAGCACATTCCAAACTTTAGCAACAGTTATCACACTTTGTAATTTGCAAAGAAAAGTTTCACCTGTATTGAATCAGAATGCCTTC AACTGAAAAAAACATATCCAAAATAATGAGGAAATGTGTTGGCTCACTACGTAGAGTCCAGAGGGACAGTCAGTTTTAGGGTTGCCTGTA TCCAGTAACTCGGGGCCTGTTTCCCCGTGGGTCTCTGGGCTGTCAGCTTTCCTTTCTCCATGTGTTTGATTTCTCCTCAGGCTGGTAGCA AGTTCTGGATCTTATACCCAACACACAGCAACATCCAGAAATAAAGATCTCAGGACCCCCCAGCAAGTCGTTTTGTGTCTCCTTGGACTG AGTTAAGTTACAAGCCTTTCTTATACCTGTCTTTGACAAAGAAGACGGGATTGTCTTTACATAAAACCAGCCTGCTCCTGGAGCTTCCCT GGACTCAACTTCCTAAAGGCATGTGAGGAAGGGGTAGATTCCACAATCTAATCCGGGTGCCATCAGAGTAGAGGGAGTAGAGAATGGATG TTGGGTAGGCCATCAATAAGGTCCATTCTGCGCAGTATCTCAACTGCCGTTCAACAATCGCAAGAGGAAGGTGGAGCAGGTTTCTTCATC TTACAGTTGAGAAAACAGAGACTCAGAAGGGCTTCTTAGTTCATGTTTCCCTTAGCGCCTCAGTGATTTTTTCATGGTGGCTTAGGCCAA AAGAAATATCTAACCATTCAATTTATAAATAATTAGGTCCCCAACGAATTAAATATTATGTCCTACCAACTTATTAGCTGCTTGAAAAAT ATAATACACATAAATAAAAAAATATATTTTTCATTTCTATTTCATTGTTAATCACAACTACTTACTAAGGAGATGTATGCACCTATTGGA CACTGTGCAACTTCTCACCTGGAATGAGATTGGACACTGCTGCCCTCATTTTCTGCTCCATGTTGGTGTCCATATAGTACTTGATTTTTT ATCAGATGGCCTGGAAAACCCAGTCTCACAAAAATATGAAATTATCAGAAGGATTATAGTGCAATCTTATGTTGAAAGAATGAACTACCT CACTAGTAGTTCACGTGATGTCTGACAGATGTTGAGTTTCATTGTGTTTGTGTGTTCAAATTTTTAAATATTCTGAGATACTCTTGTGAG GTCACTCTAATGCCCTGGGTGCCTTGGCACAGTTTTAGAAATACCAGTTGAAAATATTTGCTCAGGAATATGCAACTAGGAAGGGGCAGA ATCAGAATTTAAGCTTTCATATTCTAGCCTTCAGTCTTGTTCTTCAACCATTTTTAGGAACTTTCCCATAAGGTTATGTTTTCCAGCCCA GGCATGGAGGATCACTTGAGGCCAAGAGTTCGAGACCAGCCTGGGGAACTTGGCTGGACCTCCGTTTCTACGAAATAAAAATAAAAAAAT >57023_57023_2_NAALADL2-AMACR_NAALADL2_chr3_175042114_ENST00000454872_AMACR_chr5_34006004_ENST00000382072_length(amino acids)=479AA_BP=361 MGENEASLPNTSLQGKKMAYQKVHADQRAPGHSQYLDNDDLQATALDLEWDMEKELEESGFDQFQLDGAENQNLGHSETIDLNLDSIQPA TSPKGRFQRLQEESDYITHYTRSAPKSNRCNFCHVLKILCTATILFIFGILIGYYVHTNCPSDAPSSGTVDPQLYQEILKTIQAEDIKKS FRNLVQLYKNEDDMEISKKIKTQWTSLGLEDVQFVNYSVLLDLPGPSPSTVTLSSSGQCFHPNGQPCSEEARKDSSQDLLYSYAAYSAKG TLKAEVIDVSYGMADDLKRIRKIKNVTNQIALLKLGKLPLLYKLSSLEKAGFGGVLLYIDPCDLPKTVNPSHDTFMVSLNPGGDPSTPGY PSVGVMEKLQLGPEILQRENPRLIYARLSGFGQSGSFCRLAGHDINYLALSGGRNSIFKFFSVENSEIESVGSTSRTEHVGWWSTFLYDL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for NAALADL2-AMACR |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for NAALADL2-AMACR |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for NAALADL2-AMACR |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | C0033578 | Prostatic Neoplasms | 3 | CTD_human | |
Tgene | C0376358 | Malignant neoplasm of prostate | 3 | CTD_human | |
Tgene | C1858328 | Bile acid synthesis defect, congenital, 4 | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C3280428 | Alpha-Methylacyl-CoA Racemase Deficiency | 3 | CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0023893 | Liver Cirrhosis, Experimental | 2 | CTD_human | |
Tgene | C0001430 | Adenoma | 1 | CTD_human | |
Tgene | C0009402 | Colorectal Carcinoma | 1 | CTD_human | |
Tgene | C0009404 | Colorectal Neoplasms | 1 | CTD_human | |
Tgene | C0011195 | Dejerine-Sottas Disease (disorder) | 1 | CTD_human | |
Tgene | C0019816 | Hereditary, Type VII, Motor and Sensory Neuropathy | 1 | CTD_human | |
Tgene | C0023895 | Liver diseases | 1 | CTD_human | |
Tgene | C0027888 | Hereditary Motor and Sensory Neuropathies | 1 | CTD_human | |
Tgene | C0036341 | Schizophrenia | 1 | PSYGENET | |
Tgene | C0086565 | Liver Dysfunction | 1 | CTD_human | |
Tgene | C0205646 | Adenoma, Basal Cell | 1 | CTD_human | |
Tgene | C0205647 | Follicular adenoma | 1 | CTD_human | |
Tgene | C0205648 | Adenoma, Microcystic | 1 | CTD_human | |
Tgene | C0205649 | Adenoma, Monomorphic | 1 | CTD_human | |
Tgene | C0205650 | Papillary adenoma | 1 | CTD_human | |
Tgene | C0205651 | Adenoma, Trabecular | 1 | CTD_human |